Attention Deficit Hyperactivity Disorder
Auriga Laboratories Obtains Rights to Market and Sell a New Product Indicated for the Treatment of ADHD
Published in Health Business Week, December 21st, 2007
Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company, announced the signing of a license agreement with Outlook Pharmaceuticals, Inc., pursuant to which Auriga will have the exclusive rights to market and sell a new product indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in the United States. The new product combines one of the most frequently prescribed drug classes for this condition, in a unique dosage form previously not available.
ADHD treatments are one of the most frequently prescribed product classes in the US with over 35 million prescriptions written by physicians, generating estimated sales of over $3.5...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2007-12-21)
More Articles from Health Business Week
- A.D.A.M., Inc.
Fluke Corporation Adds Benergy by A.D.A.M. - A.M. Best Co.
Best's Review: the Boom in Multiple Births Is Costing Health Insurers Dearly, Best's Review Magazine Reports - AARP
AARP Urges Governor to Use Budget to Improve New Yorkers' Quality of Life - AARP
Divided We Fail Presidential Side-by-Side to Reach 23M+ AARP Members - AARP
Tennis Legend Martina Navratilova Signs on as AARP's New Health & Fitness Ambassador - Abbott
Status: - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
